For research use only. Not for therapeutic Use.
Fosravuconazole（Cat No.:I006606）is a triazole antifungal agent designed for the treatment of invasive fungal infections. It exhibits potent activity against a wide range of fungi, including Candida, Aspergillus, and other molds. By inhibiting fungal lanosterol 14α-demethylase, it disrupts ergosterol biosynthesis, essential for fungal cell membrane integrity. Its oral bioavailability and prolonged half-life make it an effective option for treating systemic fungal infections. Fosravuconazole is primarily used in immunocompromised patients to manage invasive fungal diseases and is undergoing further clinical evaluation for broader applications.
| Catalog Number | I006606 |
| CAS Number | 351227-64-0 |
| Synonyms | Fosravuconazole; BEF-1224; BMS-379224; E-1224; BEF1224; BMS379224; E1224.;(((2R,3R)-3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-yl)oxy)methyl dihydrogen phosphate |
| Molecular Formula | C23H20F2N5O5PS |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | [(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl dihydrogen phosphate |
| InChI | InChI=1S/C23H20F2N5O5PS/c1-15(22-29-21(10-37-22)17-4-2-16(9-26)3-5-17)23(11-30-13-27-12-28-30,34-14-35-36(31,32)33)19-7-6-18(24)8-20(19)25/h2-8,10,12-13,15H,11,14H2,1H3,(H2,31,32,33)/t15-,23+/m0/s1 |
| InChIKey | SYTNEMZCCLUTNX-NPMXOYFQSA-N |
| SMILES | C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)OCOP(=O)(O)O |
